Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Use of NPSP558 in the Treatment of Hypoparathyroidism (REPLACE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00732615
Recruitment Status : Completed
First Posted : August 12, 2008
Results First Posted : March 6, 2015
Last Update Posted : June 3, 2021
Information provided by (Responsible Party):
Takeda ( Shire )

Brief Summary:
Use of PTH (1-84) a recombinant hormone in escalating doses for the treatment of adults with hypoparathyroidism. The use of PTH should result in a decrease of calcium and vitamin D supplements.

Condition or disease Intervention/treatment Phase
Hypoparathyroidism Drug: Placebo Drug: NPSP558 Phase 3

Detailed Description:
Patients with a history of hypoparathyroidism will be randomized to receive placebo or study drug for 24 weeks, which will be injected daily in either thigh. During that time they will be monitored for safety (specifically, calcium levels in the blood and urine). In addition, the patients' intake of Vitamin D and calcium will be measured.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 124 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]) for the Treatment of Adults With Hypoparathyroidism
Actual Study Start Date : December 18, 2008
Actual Primary Completion Date : September 28, 2011
Actual Study Completion Date : September 28, 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Placebo
Sterile water for injection
Drug: Placebo
Placebo for subcutaneous injection

Experimental: 50, 75, 100 mcg NPSP558
Initial dose of 50mcg, to be titrated up to 75mcg and then 100mcg dependent upon response
Drug: NPSP558
Parathyroid hormone 50, 75, or 100 mcg injectable subcutaneously daily

Primary Outcome Measures :
  1. The Percentage of Subjects Who Met the Triple Efficacy Endpoint Criteria at Week 24. [ Time Frame: Week 24 of dosing ]
    The triple efficacy endpoint criteria were defined as at least a 50% reduction from the baseline in oral calcium dose and at least a 50% reduction from the baseline in active vitamin D dose and an albumin-corrected total serum calcium concentration that was maintained or normalized compared to the baseline value (≥ 7.5 mg/dL) and did not exceed the upper limit of the laboratory normal range. The analysis of primary efficacy endpoint was based on investigator prescribed data.

Secondary Outcome Measures :
  1. Percentage Changes From Baseline in Daily Calcium Dose at Week 24. [ Time Frame: 24 Weeks ]
    The analysis of this endpoint was based on investigator prescribed data.

  2. Proportion of Subjects Who Achieved Independence From Active Vitamin D and an Oral Calcium Dose of ≤ 500 mg/Day at Week 24. [ Time Frame: 24 Weeks ]
    Subjects Who Achieved Independence from Active Vitamin D Usage and with Calcium Dose of 500 mg/day or less. This analysis was based on Investigator Prescribed Data.

  3. Percentage of Subjects With Any Clinical Symptoms of Hypocalcemia During Weeks 16-24. [ Time Frame: 8 Weeks ]
    Clinical symptoms were a selected group of adverse events that occurred during study weeks 16 through 24. The group of terms were defined by key opinion leaders and documented in study protocol.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Patients who meet all of the following inclusion criteria can be enrolled and potentially randomized into this study:

  • Adult males or females 18 to 85 years of age (prior to screening)
  • History of hypoparathyroidism for ≥ 18 months
  • Requirement for vitamin D metabolite/analog therapy with calcitriol ≥0.25 μg per day or alphacalcidol ≥0.50 μg per day prior to randomization. Requirement for supplemental oral calcium treatment ≥ 1000 mg per day over and above normal dietary calcium intake
  • Serum thyroid function tests within normal laboratory limits at screening
  • Serum magnesium levels within laboratory normal limits
  • Serum 25-hydroxyvitamin D [25(OH)D] level ≤ 1.5-fold the laboratory upper limit of normal
  • Creatinine clearance > 30 mL/min on two separate measurements OR creatinine clearance > 60 mL/min AND serum creatinine < 1.5 mg/dL
  • With regard to female patients: women who are postmenopausal and women who are surgically sterilized can be enrolled. Women of childbearing potential must have a negative pregnancy test at Randomization and be willing to use two medically acceptable methods of contraception for the duration of the study.

Exclusion Criteria

Patients who have any of the following during the screening visit are not eligible for enrollment in this study:

  • Known history of hypoparathyroidism resulting from an activating mutation in the CaSR gene or impaired responsiveness to PTH (pseudohypoparathyroidism)
  • Any disease that might affect calcium metabolism or calcium-phosphate homeostasis other than hypoparathyroidism, such as active hyperthyroidism, Paget's disease, insulin dependent diabetes mellitus (IDDM) or poorly controlled Type II diabetes mellitus (HbA1C > 8%), severe and chronic cardiac, liver or renal disease, Cushing's syndrome, neuromuscular disease such as rheumatoid arthritis, myeloma, pancreatitis, malnutrition, rickets, recent prolonged immobility, active malignancy, primary or secondary hyperparathyroidism, a history of parathyroid carcinoma, hypopituitarism, acromegaly, or multiple endocrine neoplasia types I and II
  • Patients with a history of thyroid cancer must be documented to be disease-free for a period of at least 5 years
  • Patients dependent on regular parenteral calcium infusions (eg calcium gluconate) to maintain calcium homeostasis
  • Patients that have undergone gastric resection or have active peptic ulcer disease requiring medical therapy
  • Use of prohibited medications such as loop and thiazide diuretics, raloxifene hydrochloride, lithium, estrogens and progestins for hormone replacement therapy,methotrexate, or systemic corticosteroids within respective prohibited periods
  • Previous treatment with PTH-like drugs, including PTH(1-84), PTH(1-34) or other N-terminal fragments or analogs of PTH or PTH-related protein within 6 months prior to screening
  • Other drugs known to influence calcium and bone metabolism, such as calcitonin, fluoride tablets, or cinacalcet hydrochloride within the prohibited period
  • Use of oral bisphosphonates within the previous 6 months or IV bisphosphonate preparations within the previous 12 months prior to screening
  • Seizure disorder/epilepsy with a history of a seizure within the previous 6 months prior to screening
  • Presence of open epiphyses
  • Irradiation (radiotherapy) to the skeleton within 5 years
  • Serum 25-hydroxyvitamin D levels greater than 1.5-fold the laboratory upper limit of normal
  • Participation in any other investigational trial in which receipt of investigational drug or device occurred within 6 months prior to screening for this study
  • Pregnant or lactating women
  • History of diagnosed drug or alcohol dependence within the previous 3 years
  • Clinical history of renal calculi within the past 12 months
  • History of gout
  • Disease processes that may adversely affect gastrointestinal absorption, including but not limited to short bowel syndrome, bowel resection, tropical sprue, celiac disease, ulcerative colitis, and Crohn's disease
  • Chronic/severe cardiac disease including but not limited to cardiac insufficiency, arrhythmias, bradycardia (resting heart rate < 60 beats/minute), or hypotension (systolic and diastolic blood pressures < 100 and 60 mmHg, respectively)
  • History of cerebrovascular accident (CVA).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00732615

Show Show 31 study locations
Sponsors and Collaborators
Layout table for investigator information
Study Director: Study Director Takeda
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Shire Identifier: NCT00732615    
Other Study ID Numbers: CL1-11-040
2008-005063-34 ( EudraCT Number )
First Posted: August 12, 2008    Key Record Dates
Results First Posted: March 6, 2015
Last Update Posted: June 3, 2021
Last Verified: May 2021
Keywords provided by Takeda ( Shire ):
Additional relevant MeSH terms:
Layout table for MeSH terms
Parathyroid Diseases
Endocrine System Diseases